SAN FRANCISCO, June 1 /PRNewswire-FirstCall/ -- Medizone International, Inc. (OTC Bulletin Board: MZEI) announced another breakthrough today in its relentless pursuit to fully exploit the antimicrobial potential of AsepticSure™. Work just completed by its research team at Queen's University has now demonstrated the AsepticSure™ system can reliably eliminate in excess of 7 logs (99.99999%) of Listeria monocytogenes and Salmonella typhium with 30 minutes exposure to its unique and patented gas mixture. "The CDC estimates that food-borne illness caused by these and other contaminants such as E coli affects 76 million people in the United States each year, leading to about 300,000 hospitalizations, and 5,000 deaths," stated Dr. Michael Shannon, Medizone's Director of Medical Affairs. "Although our main commercial thrust must remain focused on Hospital Acquired Infections, the list of very real applications for our system continues to grow. Deaths from food-borne illness in the United States remains a serious public health concern as it now accounts for more deaths on an annual basis than the cumulative military losses in Iraq since 2003 (4400). These are staggering statistics and in all conscience, cannot be ignored."
Medizone's Chairman and CEO, Edwin Marshall added, "Our recent work with Listeria monocytogenes and Salmonella typhium was a direct result of a commercial inquiry from a cheese manufacturer who had recently suffered a multi-million dollar judgment against them related to these pathogens. Clearly the scope of our AsepticSure™ technology is vast and the commercial prospects nearly unlimited. With the anticipated start of our hospital beta test program imminent and the publication of peer reviewed journal literature on the science anticipated late summer, it is clear full commercialization is within view."
Medizone International, Inc., is a research and development company engaged in developing its AsepticSure™ System to decontaminate and sterilize hospital surgical suites, emergency rooms, intensive care units, schools and other critical infrastructure. A government variant is being developed for bio-terrorism counter measures.
This Press Release contains certain forward looking statements that involve substantial risks and uncertainties, including, but not limited to, the results of ongoing clinical studies, economic conditions, product and technology development, production efficiencies, product demand, competitive products, competitive environment, successful testing and government regulatory issues. Additional risks are identified in the company's filings made with the Securities and Exchange Commission.
SOURCE Medizone International, Inc.